Ebook: endoCANNABINOIDS: Actions at Non-CB1/CB2 Cannabinoid Receptors

This book is intended as a scientific resource for cannabinoid researchers carrying out animal and human experiments, and for those who are interested in learning about future directions in cannabinoid research. Additionally, this book may be of value to investigators currently working outside the field of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease.

---

The cloning of two G protein-coupled cannabinoid receptors, termed CB₁ and CB₂, in the early 1990s has stimulated and facilitated research conducted on the physiological function of cannabinoid actions in the brain and throughout the body. In the twenty years since the identification of these two receptors, endogenous ligands (endocannabinoids) for these receptors have been identified, their biosynthetic and metabolic pathways have been discerned, and their functional and regulatory action for signalling through CB₁ and CB₂ receptors have been described. More recently, it has become has become evident that cannabinoids exert actions at non-CB₁, non-CB₂ receptors. Much less is understood about these actions. Many of these novel “targets” are in the process of being characterized functionally and physiologically, and the therapeutic value of targeting these non-CB₁, non-CB₂ receptors is being evaluated. The purpose of this volume is to present the current knowledge on the atypical actions of cannabinoids on these new targets.

This book is intended as a scientific resource for cannabinoid researchers carrying out animal and human experiments, and for those who are interested in learning about future directions in cannabinoid research. Additionally, this book may be of value to investigators currently working outside the field of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease.

---

The cloning of two G protein-coupled cannabinoid receptors, termed CB₁ and CB₂, in the early 1990s has stimulated and facilitated research conducted on the physiological function of cannabinoid actions in the brain and throughout the body. In the twenty years since the identification of these two receptors, endogenous ligands (endocannabinoids) for these receptors have been identified, their biosynthetic and metabolic pathways have been discerned, and their functional and regulatory action for signalling through CB₁ and CB₂ receptors have been described. More recently, it has become has become evident that cannabinoids exert actions at non-CB₁, non-CB₂ receptors. Much less is understood about these actions. Many of these novel “targets” are in the process of being characterized functionally and physiologically, and the therapeutic value of targeting these non-CB₁, non-CB₂ receptors is being evaluated. The purpose of this volume is to present the current knowledge on the atypical actions of cannabinoids on these new targets.

This book is intended as a scientific resource for cannabinoid researchers carrying out animal and human experiments, and for those who are interested in learning about future directions in cannabinoid research. Additionally, this book may be of value to investigators currently working outside the field of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease.

Content:
Front Matter....Pages i-xi
Front Matter....Pages 1-1
Overview of Nonclassical Cannabinoid Receptors....Pages 3-27
Overview of Non-CB1/CB2 Cannabinoid Receptors: Chemistry and Modeling....Pages 29-51
Front Matter....Pages 53-53
GPR55 in the CNS....Pages 55-69
The Role of GPR55 in Bone Biology....Pages 71-113
The Role of GPR55 in Cancer....Pages 115-133
GPR18 and NAGly Signaling: New Members of the Endocannabinoid Family or Distant Cousins?....Pages 135-142
Cannabinoid Signaling Through Non-CB1R/Non-CB2R Targets in Microglia....Pages 143-171
Front Matter....Pages 173-173
Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors....Pages 175-197
Nonpsychoactive Cannabinoid Action on 5-HT3 and Glycine Receptors....Pages 199-218
Front Matter....Pages 219-219
Peroxisome Proliferator-Activated Receptors and Inflammation....Pages 221-233
Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction....Pages 235-260
Front Matter....Pages 261-261
Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors....Pages 263-280
Back Matter....Pages 281-286

---

The cloning of two G protein-coupled cannabinoid receptors, termed CB₁ and CB₂, in the early 1990s has stimulated and facilitated research conducted on the physiological function of cannabinoid actions in the brain and throughout the body. In the twenty years since the identification of these two receptors, endogenous ligands (endocannabinoids) for these receptors have been identified, their biosynthetic and metabolic pathways have been discerned, and their functional and regulatory action for signalling through CB₁ and CB₂ receptors have been described. More recently, it has become has become evident that cannabinoids exert actions at non-CB₁, non-CB₂ receptors. Much less is understood about these actions. Many of these novel “targets” are in the process of being characterized functionally and physiologically, and the therapeutic value of targeting these non-CB₁, non-CB₂ receptors is being evaluated. The purpose of this volume is to present the current knowledge on the atypical actions of cannabinoids on these new targets.

This book is intended as a scientific resource for cannabinoid researchers carrying out animal and human experiments, and for those who are interested in learning about future directions in cannabinoid research. Additionally, this book may be of value to investigators currently working outside the field of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease.

Content:
Front Matter....Pages i-xi
Front Matter....Pages 1-1
Overview of Nonclassical Cannabinoid Receptors....Pages 3-27
Overview of Non-CB1/CB2 Cannabinoid Receptors: Chemistry and Modeling....Pages 29-51
Front Matter....Pages 53-53
GPR55 in the CNS....Pages 55-69
The Role of GPR55 in Bone Biology....Pages 71-113
The Role of GPR55 in Cancer....Pages 115-133
GPR18 and NAGly Signaling: New Members of the Endocannabinoid Family or Distant Cousins?....Pages 135-142
Cannabinoid Signaling Through Non-CB1R/Non-CB2R Targets in Microglia....Pages 143-171
Front Matter....Pages 173-173
Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors....Pages 175-197
Nonpsychoactive Cannabinoid Action on 5-HT3 and Glycine Receptors....Pages 199-218
Front Matter....Pages 219-219
Peroxisome Proliferator-Activated Receptors and Inflammation....Pages 221-233
Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction....Pages 235-260
Front Matter....Pages 261-261
Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors....Pages 263-280
Back Matter....Pages 281-286
....